Smac/DIABLO protein acts as an independent prognostic factor in oral squamous cell carcinoma.

Autor: Vieira E Silva FF; Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes), Faculty of Medicine and Dentistry, University of Santiago de Compostela, San Francisco Street, s/n, Santiago de Compostela, 15782, Spain.; Health Research Institute of Santiago de Compostela (FIDIS), ORALRES Group, Santiago de Compostela University Clinical Hospital, University of Santiago de Compostela, Choupana Street, s/n, Santiago de Compostela, 15706, Spain.; Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via Abramo Lincoln, 5, Caserta, 81100, Italy., Caponio VCA; Department of Clinical and Experimental Medicine, University of Foggia, Via Napoli, 20, Foggia, 71122, Italy., Ballini A; Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via Abramo Lincoln, 5, Caserta, 81100, Italy. andrea.ballini@unifg.it.; Department of Clinical and Experimental Medicine, University of Foggia, Via Napoli, 20, Foggia, 71122, Italy. andrea.ballini@unifg.it., Chamorro-Petronacci CM; Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes), Faculty of Medicine and Dentistry, University of Santiago de Compostela, San Francisco Street, s/n, Santiago de Compostela, 15782, Spain.; Health Research Institute of Santiago de Compostela (FIDIS), ORALRES Group, Santiago de Compostela University Clinical Hospital, University of Santiago de Compostela, Choupana Street, s/n, Santiago de Compostela, 15706, Spain., Lourenzo-Pouso AI; Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes), Faculty of Medicine and Dentistry, University of Santiago de Compostela, San Francisco Street, s/n, Santiago de Compostela, 15782, Spain., García-García A; Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes), Faculty of Medicine and Dentistry, University of Santiago de Compostela, San Francisco Street, s/n, Santiago de Compostela, 15782, Spain.; Health Research Institute of Santiago de Compostela (FIDIS), ORALRES Group, Santiago de Compostela University Clinical Hospital, University of Santiago de Compostela, Choupana Street, s/n, Santiago de Compostela, 15706, Spain., Di Domenico M; Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via Abramo Lincoln, 5, Caserta, 81100, Italy., Suaréz-Peñaranda JM; Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes), Faculty of Medicine and Dentistry, University of Santiago de Compostela, San Francisco Street, s/n, Santiago de Compostela, 15782, Spain.; Health Research Institute of Santiago de Compostela (FIDIS), ORALRES Group, Santiago de Compostela University Clinical Hospital, University of Santiago de Compostela, Choupana Street, s/n, Santiago de Compostela, 15706, Spain., Pérez-Sayáns M; Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes), Faculty of Medicine and Dentistry, University of Santiago de Compostela, San Francisco Street, s/n, Santiago de Compostela, 15782, Spain.; Health Research Institute of Santiago de Compostela (FIDIS), ORALRES Group, Santiago de Compostela University Clinical Hospital, University of Santiago de Compostela, Choupana Street, s/n, Santiago de Compostela, 15706, Spain.; Materials Institute of Santiago de Compostela (iMATUS), Avenida do Mestre Mateo, 25, Santiago de Compostela, 15782, Spain., Padín-Iruegas ME; Human Anatomy and Embryology Area, Department of Functional Biology and Health Sciences, University of Vigo, Lagoas-Marcosende, s/n, Vigo, 36310, Spain.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Dec 03; Vol. 14 (1), pp. 30065. Date of Electronic Publication: 2024 Dec 03.
DOI: 10.1038/s41598-024-76962-1
Abstrakt: Oral squamous cell carcinoma (OSCC) poses significant health risks with increasing incidence and mortality rates. In this context, there is an urgent need to explore novel biomarkers to enhance therapeutic strategies and improve survival. Understanding apoptotic evasion in cancer pathogenesis, this pioneering study aims to investigate the correlation between a pro-apoptotic protein Smac/DIABLO and patient prognosis within the OSCC cohort. Immunohistochemistry (IHC) was employed to analyze Smac/DIABLO protein expression and correlate with clinicopathological and prognostic factors during a long-term follow-up. Smac/DIABLO low expression was associated with worse overall survival (OS), relapse-free survival (RFS), disease-specific survival (DSS), and an increase in risk of lymph node metastasis (LNM) in univariate analyses. Furthermore, multivariate analyses confirmed Smac/DIABLO as an independent prognostic factor, predicting poorer OS [Hazard Ratio (HR) = 3.6 (95% CI 1.7-7.6), p < 0.001], RFS [HR = 2.9 (95% CI 1.4-5.6), p = 0.003], DSS [HR = 6.7 (95% CI 2.7-16.7), p < 0.001], and increased likelihood of LNM [Odds Ratio (OR) = 4.8 (95% CI 1.4-15.9), p = 0.011]. Patients with positive Smac/DIABLO expression exhibited three times higher survival probability. Low proapoptotic protein Smac/DIABLO expression significantly influences prognostic predictions and strongly correlates with poor OSCC outcomes. Future studies involving Smac-mimetic drugs in OSCC are needed to evaluate their pro-apoptotic potential in cancer cells.
Competing Interests: Declarations. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: